Expression of the fusogenic p14 FAST protein from a replication-defective adenovirus vector does not provide a therapeutic benefit in an immunocompetent mouse model of cancer

CM Wong1,2,3, LA Nash1,2,3, J Del Papa1,2,3, KL Poulin1, T Falls4, JC Bell2,4,5 and RJ Parks1,2,3,5

When injected directly into a tumor mass, adenovirus (Ad) vectors only transduce cells immediately along the injection tract. Expression of fusogenic proteins from the Ad vector can lead to syncytium formation, which efficiently spreads the therapeutic effect. Fusogenic proteins can also cause cancer cell death directly, and enhance the release of exosome-like particles containing tumor-associated antigens, which boosts the anti-tumor immune response. In this study, we have examined whether delivery of an early region 1 (E1)-deleted, replication-defective Ad vector encoding the reptilian reovirus p14 fusion-associated small transmembrane (FAST) protein can provide therapeutic efficacy in an immunocompetent mouse tumor model. A high multiplicity of infection of AdFAST is required to induce cell fusion in mouse mammary carcinoma 4T1 cells in vitro, and FAST protein expression caused a modest reduction in cell membrane integrity and metabolic activity compared with cells infected with a control vector. Cells expressing FAST protein released significantly higher quantities of exosomes. In immunocompetent Balb/C mice harboring subcutaneous 4T1 tumors, AdFAST did not induce detectable cancer cell fusion, promote tumor regression or prolong mouse survival compared with untreated mice. This study suggests that in the context of the 4T1 model, Ad-mediated FAST protein expression did not elicit a therapeutic effect.

Cancer Gene Therapy (2016) 23, 355–364; doi:10.1038/cgt.2016.41; published online 14 October 2016

INTRODUCTION
Finding new and effective therapeutics is an ongoing challenge in the cancer field. Over the years, many pre-clinical research efforts and clinical trials have utilized viruses in an attempt to combat the disease. Indeed, an oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor has recently been approved for clinical use in North America.1 For one of the most commonly used gene therapy vectors, adenovirus (Ad), two Ad-based vectors have been approved for cancer treatment in China—a non-replicating Ad encoding p53, termed Gendicine, and an oncolytic Ad deficient in the E1B-55 kD protein.2 However, a common problem with Ad is their restricted ability to disperse throughout a tumor, particularly following direct intratumoral injection.3–5 Typically, Ad infection is limited to a 5 mm area surrounding the injection tract, which prevents efficient transgene product delivery to all cells of the tumor.4 Although this may not be a significant issue when Ad is used to delivery the gene for secreted proteins, such as cytokines, it may limit the efficacy of other types of therapeutic genes and proteins, which require expression directly within the cell to exert their effect, such as, for example, the tumor suppressor p53.

To increase the proportion of the tumor impacted by the Ad vector, several research groups have encoded genes for fusogenic proteins within the vector. Infection of a single cell would result in expression of the fusogenic protein and any other encoded, therapeutic protein, and subsequent cell–cell fusion would amplify the therapeutic effect to a greater percentage of the tumor mass. Various viruses have been modified to express membrane fusion proteins from Gibbon ape leukemia virus (GALV), respiratory syncytial virus (RSV), measles virus (MV), Newcastle disease virus and human immunodeficiency virus type 1 (HIV-1), and in many studies these vectors were shown to be effective in tumor regression.6–14 Ad vectors expressing GALV, RSV, MV or vesicular stomatitis virus (VSV) membrane fusion proteins as a sole anti-cancer agent were able to reduce tumor burden in xenograft and immunocompetent mouse models in the absence of other complementing anti-cancer therapeutic transgenes.8,9,12,13 Thus, in many studies, the process of cancer cell fusion, and associated disruption in cellular processes, can lead to tumor regression.

Several studies have shown that enhanced immune activation also contributes to the anti-cancer efficacy of fusogenic proteins. Cell fusion can activate a subset of interferon stimulated genes (but not interferon itself) through an interferon regulatory factor 3 (IRF3)-dependent pathway and does not require external interferon signaling.15 Expression of fusogenic proteins in cancer cells also causes the release of exosome-like molecules called syncytiosomes. These syncytiosomes contain tumor antigens and are effective in priming dendritic cells (DC) to promote an
Human lung adenocarcinoma A549 cells were grown in modified 10% FBS. All cells were kept at 37 °C and in a 5% CO₂ atmosphere.

The reptilian reovirus p14 fusion-associated small transmembrane (FAST) protein is a 125 amino acid type III transmembrane protein.\(^2\) The small size of p14 FAST relative to other fusogenic proteins is particularly attractive as it would leave sufficient cloning room within the Ad vector to accommodate additional therapeutically-relevant genes. Several studies have shown that expression of the FAST protein in cancer cells in culture can result in wide-spread syncytia formation, leading to apoptosis/cell death.\(^2\) Mice injected with VSV-expressing p14 FAST protein had higher viral titers from infected tissue in vivo, suggesting a greater ability to spread and replicate compared with the control virus.\(^2\) Co-administration of an oncolytic VSV armed with the p14 FAST protein increased oncolytic vaccinia virus titers and synergistically promoted cancer cell death in vitro.\(^2\)

In previous work, we examined whether Ad-mediated delivery of FAST to cancer cells could lead to cell death in the human adenocarcinoma A549 cell line in vitro and lead to tumor regression and increased survival in an A549 xenograft tumor model in immunodeficient mice in vivo.\(^2\) We showed that expression of FAST protein from an E1-deleted Ad vector caused extensive cell fusion of A549 cells in culture, resulting in loss of cellular metabolic activity and membrane integrity, which correlated with induction of apoptosis. Unfortunately, in the A549 xenograft CD-1 nude mouse cancer model, Ad-mediated FAST gene delivery did not induce detectable cell fusion, reduce tumor burden nor enhance mouse survival compared with the controls. However, any contribution of FAST protein-mediated activation of anti-tumor immunity could not occur in the A549 xenograft mouse model that used immunodeficient mice. Thus, we have now evaluated AdFAST efficacy in an immunocompetent mouse of cancer.

**MATERIALS AND METHODS**

**Cell culture**

Mouse colon carcinoma CT26, melanoma B16F10 and mammary carcinoma 4T1 cells were maintained in Dulbecco’s Modified Eagle Medium (DMEM) (Sigma Aldrich, Oakville, ON, Canada) supplemented with 10% (v/v) fetal bovine serum (FBS) (Sigma Aldrich), 2 mM GlutaMAX (Invitrogen, Waltham, MA, USA) and 1 × antibiotic-antimycotic (Invitrogen). Human lung adenocarcinoma A549 cells were grown in Modified Eagle Medium (MEM) with similar supplements. Cells infected with Ad were maintained in medium described above, except with 5% FBS instead of 10% FBS. All cells were kept at 37 °C and in a 5% CO₂ atmosphere.

**Adenoviral constructs and adenovirus purification**

All vectors used in the study are based on early region 1 (E1)- and E3-deleted Ad serotype 5, and have been described previously.\(^2\) AdEmpty does not encode a transgene.\(^2\) AdRFP expresses the monomeric red fluorescent protein (a kind gift of Roger Tsien, University of California, San Diego\(^2\)) under the control of the human cytomegalovirus (CMV) enhancer/promoter and bovine growth hormone polyadenylation sequence (BGHPa).\(^2\) AdmCherry is similar in structure to AdRFP, but expresses the mCherry mutant of the Discosoma sp. red fluorescent protein.\(^2\) AdFAST contains the p14 FAST open reading frame under regulation by the CMV enhancer/promoter and BGHPa.\(^2\) AdFAST-HA has been previously described,\(^2\) and is similar in structure to AdFAST, but contains an HA epitope tag on the C terminus of the FAST protein. AdFAST/RFP expresses the FAST protein and RFP under separate CMV promoters and BGHPa.\(^2\) AdGAL has the E. coli β-galactosidase gene under control by the CMV enhancer/promoter.\(^2\) Adenoviral stocks were amplified and purified as described previously.\(^2\)

**Fluorescence microscopy**

CT26, B16F10 and 4T1 cells were seeded at a density of 0.8 × 10⁵ cells per 35 mm plate. Next day, the cells were infected at a multiplicity of infection (MOI) of 50 with AdRFP or AdFAST/RFP for 1 h in 200 μl inoculum. Two ml of media was added and cells were viewed using the Zeiss Axiosvert 200 M microscope (North York, ON, Canada) (20 × objective) every 24 h.

**Membrane integrity assays**

CT26, B16F10 and 4T1 cells were seeded at 2 × 10⁶ cells per well in 96 well plates and grown to sub-confluence. Cells were infected at varying MOI with AdEmpty or AdFAST in a final volume for 1 h, followed by addition of 100 μl of 5% FBS/DMEM. For all experiments, the VSVΔ51 virus and cells lysed using 9% Triton X-100 for 45 min before starting the assay were used as positive controls. Each treatment condition was conducted in triplicate. Seventy-two hours post infection, 50 μl from each well was transferred to a new 96 well plate. To examine membrane permeability, the CytoTOX-ONE Homogeneous Membrane Integrity Assay kit (Promega, Madison, WI, USA) was used according to the manufacturer’s instructions. Fluorescence readings were obtained using a 544 nm excitation and 590 nm emission filter on the Fluostar Galaxy fluorimeter (BMG Labtech, Guelph, ON, Canada).

**Ad infectivity and promoter activity**

4T1 and A549 cells were plated at a density of 0.8 × 10⁵ cells per 35 mm dish. When plates were confluent, cells were infected with Adβ-Gal at an MOI of 1. Twenty-four hours post infection, cells were either fixed and stained with 50 μl mI-1 X-gal overnight or collected to determine β-galactosidase activity using the Galacto-Star β-Galactosidase Reporter Gene Assay System for Mammalian Cells (Applied Biosystems, Thermo-fisher, Waltham, MA, USA). Chemiluminescent activity was determined using a 20/20i luminometer (Turner Biosystems, Madison, WI, USA).

**Immunoblot analysis**

4T1 cells were seeded at 1 × 10⁶ cells per 35 mm dish. Next day, the cells were infected for 1 h at the indicated MOI of Ad virus. Following a 48 or 72 h incubation, whole-cell lysates were collected using 2 × SDS/PAGE protein loading buffer (62.5 mM Tris HCl pH 6.8, 25% glycerol, 2% SDS, 0.01% bromophenol blue, 5% β-mercaptoethanol). Samples were boiled for 5 min, separated by electrophoresis on a 15% SDS-polyacrylamide gel, and transferred onto a polyvinylidene fluoride (PVDF) membrane (Millipore, Etobicoke, ON, Canada). The resulting membrane was probed with a mouse HA tag monoclonal antibody (1:10 000, Cell Signaling (Beverly, MA, USA) #2367), rabbit cleaved caspase-3 monoclonal antibody (1:10 000, Cell Signaling #9664) or full-length caspase-3 antibody (1:1000, Cell Signaling #9662) and 1:5000 goat anti-mouse IgG antibody conjugated to horseradish peroxidase (HRP) (1:100 000, Bio-Rad #170-6516). The membrane was also probed with antibody to α-tubulin to confirm equal loading (1:5000 rabbit α-tubulin antibody, AbCam (Toronto, ON, Canada) #ab15246, 1:5000 goat anti-rabbit IgG conjugated to HRP, Bio-Rad #170-6515). Blots were developed using the Pierce Enhanced Chemiluminescent (ECL) Western Blotting Substrate (Thermo Scientific, Waltham, MA, USA).

**Giemsa staining**

4T1 cells were seeded in 4 well plates (0.15 × 10⁶ per well) and grown to confluence. Cells were infected with AdEmpty or AdFAST at an MOI of 1000 for 48 h. Cells were fixed and stained with Giemsa stain (Merck Millipore, Etobicoke, ON, Canada) and visualized using the Zeiss Axiosvert 200 M microscope (20 × objective).

**MTS metabolic activity assays**

4T1 cells were plated in 96 well plates at a density of 2 × 10⁴ cells per well. Next day, wells were infected with AdEmpty, AdmCherry, or AdFAST for 1 h in 25 μl. Following the 1 h infection, 5% FBS/MEM was added to a final volume of 100 μl. The relative metabolic activity was determined over a time course of 96 h, with 24 h intervals, using the CellTiter 96 AQueous Non-Radioactive Cell Proliferation Assay (Promega). For the assay, cells were incubated for 1 h with MTS substrate (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium). Absorbance readings were obtained at 490 nm using the SpectraMax 190 plate spectrophotometer (Molecular Devices, Sunnyvale, CA, USA).
Exosome isolation
4T1 cells were plated in 60 mm plates at a density of $1.6 \times 10^6$ cells per well. Next day, cells were infected with AdEmpty or AdFAST at an MOI of 1000 for 1 h in 500 μl. Following the 1 h infection, 5% FBS/MEM was added to a final volume of 3 ml. Media was isolated 72 h post infection, and exosomes were isolated using the Exoquick kit (System Biosciences, Mountain View, CA, USA) according to the manufacturer's instructions. Purified exosomes were analyzed by immunoblot using rabbit anti-Alix (Sigma, Oakville, Ontario, Canada) at a dilution of 1:1000, rabbit anti-Flotillin-2 (Cell Signaling, Danvers, MA, USA) at 1:1000, or HA at 1:1000. The concentration of exosome particles isolated from media was quantified using Zetaview (Particlemetrix, Germany) according to the manufacturer's instructions. Exosomes were isolated from 3–4 independent experiments, with 11 individual readings for particle size determination per sample for each experiment.

Mouse efficacy studies
All animal experiments were performed according to the guidelines and protocols approved by the Animal Care Committee at the University of Ottawa. Six week old Balb/C mice were obtained from Charles River Laboratories (Wilmington, MA, USA). Mice were injected with $1 \times 10^3$ 4T1 cells resuspended in 100 μl PBS in the right hind flank. When tumors reached $\sim 5 \times 5$ mm in size, mice were injected intratumorally with PBS or $1.9 \times 10^9$ plaque forming units (pfu) AdFAST in 50 μl PBS. Tumor size was monitored three times a week using digital calipers. Mice were euthanized when the tumors reached 15x15 mm in size (endpoint). For tissue analyses, a second group of mice were injected when 4T1 tumors reached 7x7 to 10 x 10 mm in size and treated as described above. A third group of mice were injected with $1.4 \times 10^9$ pfu AdEmpty. All mice used for histological analysis were sacrificed day 3 post vector injection and the tumor and liver were collected for further analysis. Samples were fixed with 10% formalin overnight and maintained in 70% ethanol. Samples were sectioned and stained with hematoxylin and eosin at the Morphology Unit of the Department of Pathology and Laboratory Medicine (University of Ottawa).

Statistical analysis
SigmaStat 2.0 (San Jose, CA, USA) was used to assess statistical significance for all bar graphs using one-way ANOVA and Tukey's test. When the results did not follow a normal distribution, the Kruskal–Wallis one-way ANOVA on Ranks test was used. Dunn's test was applied instead of Tukey's test when required. To compare exosome yield, statistical analysis consisted of one-way ANOVA with post-hoc analysis by the Gabriel Pairwise Comparisons Test. For survival studies, the log-rank test was used to determine statistical significance of the Kaplan–Meier survival curve with Graphpad Prism 6.0 (La Jolla, CA, USA). All statistical tests were completed with $P=0.05$.

RESULTS
Preliminary characterization of Ad infection of common mouse cancer cell lines
To examine whether AdFAST would provide a therapeutic benefit in an immunocompetent mouse model of cancer, we first examined several common mouse cancer cell lines for their susceptibility to Ad infection and FAST protein-mediated cell fusion. Mouse colon cancer CT26, melanoma B16F10 and mammary cancer 4T1 cells were infected with an E1 and E3-deleted Ad vector expressing RFP and FAST protein under the control of the CMV promoter/enhancer, and examined for gene expression and evidence of fusion 48 h later. At an MOI of 50, the CT26 cell line did not show evidence of infection, as no red cells were observed (Figure 1a). The 4T1 and B16F10 cell lines show a similar level of infection; however, neither cell line showed obvious signs of fusion at this MOI. In the human lung adenocarcinoma A549 cell line, treatment with AdFAST caused a significant decrease in cell membrane integrity at as low an MOI as 1, whereas syncytium formation was only evident at a much higher MOI.23 Thus, we examined the relative membrane permeability of these three cell lines when infected with AdEmpty or AdFAST, by determining the quantity of lactate dehydrogenase (LDH) protein released into the supernatant at 72 hpi. CT26 and B16F10 cells showed no apparent difference in membrane integrity after infection at an MOI of up to 100 (Figures 1b and c). AdFAST infected 4T1 cells showed a modest increase in membrane permeability at MOI 100 compared with cells infected with AdEmpty (Figure 1d). Thus, we chose the 4T1 cell line for further characterization.

4T1 cells have low susceptibility to Ad infection
Previously, we showed that under conditions in which AdFAST could replicate (that is, in E1-complementing 293 cells), rampant cell fusion was observed.23 However, under non-replicating conditions, high MOI of AdFAST was required to provide sufficient FAST protein expression to promote fusion, possibly due to a requirement for FAST protein to act as a multimer to mediate cell fusion.24 We therefore examined both the relative infection level and human CMV promoter activity in 4T1 versus human A549 cells, a cell line commonly used for Ad-based studies and the cell line that was used in our previous work.23 We infected 4T1 and A549 cells at an MOI of 1 with Adβ-Gal and determined the percentage of infected cells using X-gal staining and promoter activity using a chemiluminescent β-galactosidase assay 24 h later. Under these conditions, 1.2% of 4T1 cells stained blue, indicating infection by the Adβ-Gal virus, whereas A549 cells were infected at an efficiency of 5.9% (Figure 2a). Hence, Ad is able to infect and give rise to transgene expression in A549 cells approximately 5-fold more efficiently than 4T1 cells. An assessment of the promoter activity using the chemiluminescent assay showed that A549 cells had a 10.6-fold increase in reporter gene activity compared with 4T1 cells at this MOI (Figure 2b). When β-gal activity is normalized to the number of infected cells, A549 cells had an ~2.1-fold higher level of β-gal expression per infected cell compared with 4T1 cells (Figure 2c). Therefore, although the level of protein expression driven from the CMV promoter in an Ad vector is not dramatically different between the two cell lines, a higher MOI is likely required to achieve the same degree of cell infection, and thus overall level of FAST protein expression, in 4T1 cells compared with A549 cells.

We showed previously that Ad-mediated expression of FAST in A549 cells induced significant apoptosis at an MOI as low as 10.23 As 4T1 cells showed an ~10-fold reduction in ability to support Ad transgene expression compared with A549 cells, we examined whether higher MOI infection with AdFAST could induce apoptosis in the 4T1 cell line. 4T1 cells were infected with varying MOI (10–1000 pfu per cell) of AdFAST-HA, and crude protein samples were analysed 72 h later for expression of FAST and cleavage of caspase-3, a marker of apoptosis. As shown in Figure 2d, although FAST expression could be detected in cells at an MOI of 100, apoptosis was only detected at very high MOI. Similarly, using the LDH release assay to evaluate cell membrane integrity, cells infected with AdFAST at an MOI of 1000 showed an almost threefold increase in membrane permeability compared with AdEmpty infected cells at the same MOI, but this effect did not reach statistical significance (Figure 2e). Taken together, these results indicate that the relatively poor ability of Ad to infect 4T1 cells necessitates the use of high MOI to achieve the levels of FAST protein necessary to induce cell death.

FAST protein expression in 4T1 cells causes cell fusion, decreases cellular metabolic activity and induces apoptosis
We further examined the effect of FAST protein expression on 4T1 cell function by examining cell fusion and metabolic activity of AdFAST-treated cells compared with control vector. First, 4T1 cells were infected with AdEmpty or AdFAST at an MOI of 1000, and stained with Geimsa stain to aid in visualizing fused cells. As shown in Figure 3a, neither PBS nor AdEmpty-treated cells showed any evidence of cell fusion. In contrast, 4T1 cells treated with AdFAST showed altered morphology with several regions of cell

Cancer Gene Therapy (2016), 355 – 364
AdFAST for cancer therapy
CM Wong et al
fusion evident per field of view. Thus, FAST protein expression from an Ad vector can cause 4T1 cell fusion.

We next examined whether treatment of 4T1 cells with AdFAST altered cellular metabolic activity relative to control vector-treated cells. Treatment of 4T1 cells with an MOI of 1000 with AdEmpty or AdmCherry resulted in a 30–40% decrease in metabolic activity at time points beyond 24 hpi (Figure 3b). However, AdFAST caused a more pronounced decrease in metabolic activity of the cells, particularly at later time points, where an almost 80% decrease in metabolic activity was observed. Consistent with this, although we observed evidence of apoptosis in all treatment groups, AdFAST-treated cells had higher levels of the cleaved caspase-3 (Figure 3c), suggesting that AdFAST caused greater cell death.

Ad-mediated expression of FAST protein promotes exosome release from 4T1 cells

Previous studies showed that expression of fusogenic proteins in cancer cells can lead to the enhanced release of exosome-like molecules called syncytiosomes. Importantly, these syncytiosomes contain tumor antigens and are effective at priming antigen presenting cells to elicit the formation of cancer-specific T cell that can eliminate the tumor and provide long lasting anti-tumor immunity. To determine if Ad-mediated expression of FAST protein also results in the enhanced release of exosomes, we infected 4T1 cells with AdEmpty or AdFAST-HA at an MOI of 1000, and isolated exosomes from the medium 72 hpi using a commercially available kit. An analysis of particle size showed that these were indeed within the size range of exosomes (Figure 4a). Equal volumes of the resulting exosome samples were analyzed by immunoblot for the expression of two protein markers of exosomes, Alix and Flotillin. As shown in Figure 4b, protein samples from AdFAST-treated cells showed a higher level of both Alix and Flotillin suggesting enhanced quantities of exosomes were in the medium relative to mock- or AdEmpty-treated cells. Consistent with this observation, direct quantification of the number of exosomes in the isolated samples showed that there was an ~fivefold increase in exosomes released from

![Figure 1](image-url)
AdFAST-treated cells compared with AdEmpty-treated cells (Figure 4c). Therefore, Ad-mediated expression of FAST protein in 4T1 cells results in enhanced release of exosomes, which may be bioavailable to enhance immune responses to tumor-associated antigens thereby possibly contributing to therapeutic efficacy.

Ad-mediated FAST protein expression does not reduce tumor burden or promote survival in subcutaneous 4T1 tumors in immunocompetent mice.

We next examined whether AdFAST could provide a therapeutic effect in an immunocompetent 4T1 tumor model in vivo. Balb/C mice with 4T1 subcutaneous tumors were injected with PBS or $1.9 \times 10^9$ pfu AdFAST and tumor volume and survival were monitored at varying time points post-treatment. Treatment of tumor-bearing mice with AdFAST did not alter the rate of tumor growth nor did it enhance survival (Figures 5a and b). Tumors that were excised 3 days post injection showed no obvious signs of cell fusion (Figure 5c). However, in AdFAST-treated tumors, we observed numerous lesions located near tumor margins, which appeared as holes in the tissue. As we were unsure whether this was due to FAST protein expression or the Ad vector itself, we injected 4T1 tumor-bearing mice intratumorally with $1.4 \times 10^8$ pfu AdEmpty and removed the tumors 3 days post injection for analyses. AdEmpty-treated tumors also had similar lesions, indicating the effects seen were due to the Ad vector and not expression of FAST (Figure 5d). As Ad normally accumulates in the liver following both systemic delivery and local, intratumoral injection, we also collected livers at the time of sacrifice. There were no obvious differences in pathology of livers from PBS or AdFAST-treated mice (data not shown). Therefore, although AdFAST can cause fusion and alter metabolic activity of 4T1 cells in vitro, in the 4T1 immunocompetent mouse tumor model AdFAST showed no obvious therapeutic benefit in vivo.

DISCUSSION

Our previous work had examined the effects of FAST protein expression in the A549 lung adenocarcinoma model in vivo and in an A549 xenograft nude mouse model in vivo. Although we...
observed evidence of fusion and enhanced cell death \textit{in vitro},
treatment of established tumors in the immunocompromised
mice with AdFAST did not provide a therapeutic bene
fit. Previous studies have shown that part of the efficacy of fusogenic proteins
can be due to enhanced release of tumor-associated antigen-
containing exosome-like particles, referred to as syncytiosomes,
from the fused cell, which can subsequently act to stimulate
immune-mediated rejection of the tumor. 16 This effect would be
absent in our A549 xenograft studies. We therefore investigated
whether AdFAST would have a stronger therapeutic effect in an
immunocompetent mouse tumor model.

Of the three mouse cancer cell lines we investigated, we found
that Ad infected B16F10 and 4T1 tumor cells with a similar
efficiency (Figure 1a). However, infection of these two cell lines
with AdFAST showed that the 4T1 cells had a higher degree of
FAST-induced cell membrane permeability (Figures 1 and 2),
although a very high MOI was required for this effect. 4T1 cells
showed a lower overall efficiency of infection relative to A549 cells
(5-fold lower, Figure 2a) and also approximately half the relative
amount of expression per infected cell (Figure 2c). Within AdFAST,
FAST expression is regulated by the human CMV immediate early
enhancer/promoter. Previous studies have shown that the CMV
enhancer/promoter is less active in murine cells than in human
cells,37 consistent with our observations. Thus, although the 4T1
model may be adequate to evaluate the efficacy of AdFAST in an
immunocompetent mouse model, we would predict that higher
amounts of virus may be required to see an effect.

Although we achieved significant levels of FAST protein
expression in 4T1 cells, especially at high MOI (Figure 2d), we
observed only modest levels of cell fusion (Figure 3a). It is possible
that FAST protein expression caused formation of small syncytia at
lower MOIs, which were not readily detectable in our fusion assay.
However, there may be fundamental differences between human
and mouse cells that confer differences in ability to fuse. Previous
work with GALV and MV fusogenic proteins showed limited fusion
activity in mouse models, which suggests that this species may
lack cellular factors necessary for fusion. Regardless, the low-level
of fusion we observed in 4T1 cells was accompanied by a
significant decrease in metabolic activity (Figure 3b), which
appeared to progress to cell death due to caspase-3-mediated
apoptosis (Figures 2d and 3c). It is possible that a significant
amount of FAST protein may mislocalize to the membrane of
cellular organelles, such as the mitochondria, leading to metabolic
failure and ultimately cell death, as has been observed for other
fusogenic proteins.38 Cell death through this mechanism would be
independent of overt cell fusion. Nevertheless, these results
suggested that AdFAST warranted testing for efficacy \textit{in vivo}.
Treatment of 4T1 tumor-bearing mice with AdFAST did not result in enhanced survival (Figure 5a) or a reduction in tumor growth (Figure 5b). Previous studies with replication-defective Ad vectors expressing RSV or MV fusion proteins showed that although these vectors mediated limited fusion in mouse cells in vitro, they were still able to act as effective sole therapeutics to reduce tumor burden in syngeneic mouse models. A similar effect was not observed for our experiments with the FAST protein. Work by Bateman et al. demonstrated that fused syncytia have enhanced release of exosome-like particles. These syncytiosomes could load tumor-associated antigens into DC, and were more effective at stimulating anti-tumor immunity than cells dying by other means. We had hoped that a similar mechanism would occur for FAST-expressing tumor cells. Although we showed that AdFAST-treated 4T1 cells have an enhanced release of exosomes in vitro (Figure 4), this did not translate to a greater therapeutic effect in vivo. However, the 4T1 model is characterized as having a relatively low inherent immunogenicity, and any FAST-mediated indirect effects on anti-tumor immunity may be ineffective at surmounting this obstacle.

We did not observe evidence of cell fusion in tumor sections from AdFAST-treated mice (Figure 5c). However, we did observe a
large number of pockets or holes in tumor sections from animals receiving treatment with either AdEmpty or AdFAST, but not in animals injected with PBS, suggesting these structures were due to administration of the Ad vector and independent of transgene expression. Interestingly, we also observed a significant reduction in metabolic activity when 4T1 cells were treated with our two control vectors AdEmpty and AdmCherry in vitro (Figure 3b). Although these vectors are deleted of the E1 (and E3) region, and are thus largely replication-defective, they still have the ability to express some viral proteins, such as those encoded by E4. One of the E4 open reading frames, E4ORF4, is capable of inducing p53-independent cell death through a non-classical apoptotic mechanism. It is possible that low-level expression of some of these viral proteins contributes to the formation of these

Figure 5. AdFAST does not promote survival or reduce tumor growth in immunocompetent Balb/C mice with subcutaneous 4T1 tumors. (a) Kaplan–Meier survival curve for 4T1 tumor-bearing mice treated with AdFAST. Balb/C mice with subcutaneous 4T1 tumors were intratumorally injected with PBS or 1.9 \times 10^9 pfu AdFAST. Each treatment group consisted of five mice. (b) The average size of tumors treated with PBS or AdFAST as described in (a). The error bars represent the standard deviation. The + symbols show the number of mice that had reached endpoint by the time measurements were taken. (c) Subcutaneous 4T1 tumors from Balb/C mice were removed, fixed, sectioned and stained with hematoxylin and eosin stain 3 days post injection. Images are representative from a group of three mice per treatment. (d) Balb/C mice with subcutaneous 4T1 tumors were intratumorally injected with 1.4 \times 10^8 pfu AdEmpty. Three days post injection, tumors were excised, fixed, sectioned and subjected to hematoxylin and eosin stain.
structures, but the mechanism is unclear. Regardless, we did not observe a difference in rate of tumor growth between Ad- and PBS-treated animals, indicating that the presence of these structures was not associated with tumor stasis nor tumor regression.

Our study shows that Ad-mediated p14 FAST protein expression did not induce extensive cell–cell fusion and had modest effects on membrane permeability and cellular metabolic activity in the mouse cancer cell lines examined. Moreover, AdFAST did not have an enhanced therapeutic benefit in the immunocompetent 4T1 mouse mammary cancer model compared with mock-treated mice. Our results suggest that a modified treatment regime, vector modifications or additional immunostimulatory transgenes may be required to induce a therapeutic effect with AdFAST in immunocompetent in vivo models of cancer.

CONFLICT OF INTEREST
The authors declare no conflict of interest.

ACKNOWLEDGEMENTS
We would like to thank Kalisa Campbell, Natacha Provost, Melissa Geoffroy and Maddison Turner for their technical support. The Parks lab is funded by the Canadian Institutes of Health Research (CIHR), the Cancer Research Society (Canada) and the National Sciences and Engineering Research Council (NSERC). CMW and JDP were recipients of the Queen Elizabeth II Graduate Scholarship in Science and Technology from the Ontario Government. LAN was the recipients of an Ontario scholarships Doctoral Award from CIHR.

REFERENCES
1 Greig SL. Talmogene Laherparepvec: first global approval. Drugs 2016; 76: 147–154.
2 Shi J, Zheng D. An update on gene therapy in China. Curr Opin Mol Ther 2009; 11: 547–553.
3 Heise CC, Williams A, Olesch J, Kirn DH. Efficacy of a replication-competent adenovirus (ONYX-015) following intratumoral injection: intratumoral spread and distribution effects. Cancer Gene Ther 1999; 6: 499–504.
4 Lang FF, Bruner JM, Fuller GN, Aldape K, Prados MD, Chang S et al. Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results. J Clin Oncol 2003; 21: 2508–2518.
5 Smith E, Breznik J, Lichy BD. Strategies to enhance viral penetration of solid tumors. Hum Gene Ther 2011; 22: 1053–1060.
6 Ebert O, Shinozaki K, Kourioti C, Park MS, Garcia-Sastre A, Woo SL. Syncytia induction enhances the oncolytic potential of vesicular stomatitis virus in vitro therapy for cancer. Cancer Res 2004; 64: 3265–3270.
7 Fu X, Tao L, Jin A, Vile R, Brenner MK, Zhang X. Expression of a fusogenic membrane glycoprotein by an oncolytic herpes simplex virus potentiates the viral antitumor effect. Mol Ther 2003; 7: 748–754.
8 Guedan S, Grases D, Rojas JJ, Gros A, Vilardell F, Vile R et al. GALV expression enhances the therapeutic efficacy of an oncolytic adenovirus by inducing cell fusion and enhancing viral expression. Gene Ther 2011; 18: 1048–1057.
9 Hoffmann D, Bayer W, Grunwald T, Wildner O. Intratumoral expression of respiratory syncytial virus fusion protein in combination with cytokines encoded by adenoviral vectors as in situ tumor vaccine for colorectal cancer. Mol Cancer Ther 2007; 6: 1942–1950.
10 Li H, Hlavik YS, Derdeyn CA, Lam J, Coolidge C, Hunter E et al. Human immunodeficiency virus type 1-mediated syncytium formation is compatible with adenovirus replication and facilitates efficient dispersion of viral gene products and de novo-synthesized virus particles. Hum Gene Ther 2001; 12: 2155–2165.
11 Zhu B, Yang JR, Fu XP, Jiang YQ. Anti-tumor effects of gene therapy with GALV membrane glycoprotein fusion in lung adenocarcinoma. Cell Biochem Biophys 2014; 69: 577–582.
12 Hoffmann D, Bayer W, Wildner O. In situ tumor vaccination with adenovirus vectors encoding measles virus fusogenic membrane proteins and cytokines. World J Gastroenterol 2007; 13: 3063–3070.
13 Hoffmann D, Bayer W, Wildner O. Therapeutic immune response induced by intratumoral expression of the fusogenic membrane protein of vesicular stomatitis virus and cytokines encoded by adenoviral vectors. Int J Mol Med 2007; 20: 673–681.
14 Simpson GR, Horvath A, Nenns NE, Pencavel T, Metcaiff S, Seth R et al. Combination of a fusogenic glycoprotein, prodrug activation and oncolytic HSV as an intravascular therapy for superficial bladder cancer. Br J Cancer 2012; 106: 496–507.
15 Négroni RS, Taylor K, Ciechonska M, Collins SE, Duncan R, Mossman KL. Membrane perturbation elicits an lF3-dependent, interferon-independent antiviral response. J Virol 2011; 85: 10926–10931.
16 Bateman AR, Harrington KJ, Kottke T, Ahmed A, Melcher AA, Gough MJ et al. Viral fusogenic membrane glycoproteins kill solid tumor cells by nonapoptotic mechanisms that promote cross presentation of tumor antigens by dendritic cells. Cancer Res 2002; 62: 6556–6578.
17 Errington F, Jones J, Merrick A, Bateman A, Harrington K, Gough MJ et al. Fusogenic membrane-glycoprotein-mediated tumour cell fusion activates human dendritic cells for enhanced IL-12 production and T-cell priming. Gene Ther 2006; 13: 138–149.
18 Linardakis E, Bateman A, Phan V, Ahmed A, Gough M, Olivier K et al. Enhancing the efficacy of a weak allogeneic melanoma vaccine by viral fusogenic membrane glycoprotein-mediated tumor cell–tumor cell fusion. Cancer Res 2002; 62: 5495–5504.
19 Corcoran JA, Duncan R. Reptilian reovirus utilizes a small type III protein with an external myristylated amino terminus to mediate cell–cell fusion. J Virol 2004; 78: 4342–4351.
20 Duncan R, Corcoran J, Shou J, Stoltz D. Reptilian reovirus: a new fusogenic oncoreovirus. Virology 2004; 319: 131–140.
21 Le Boeuf F, Diallo JS, McCart JA, Thorne S, Falls T, Stanford M et al. Synergistic interaction between oncolytic viruses augments tumor killing. Mol Ther 2010; 18: 888–895.
22 Poulin KL, Lanthier RM, Smith AC, Christou C, Powell KL et al. Retargeting of adenovirus vectors through genetic fusion of a single-chain or single-domain antibody to capsid protein IX. J Virol 2010; 84: 10074–10086.
23 Poulin KL, Tong G, Vorozybova O, Pool M, Kohrathy R, Parks RJ. Use of Cre/loxP recombination to swap cell binding motifs on the adenoviral capsid protein IX. Virology 2011; 420: 146–155.
24 McFall ER, Murray LM, Lunde JA, Jasmin BJ, Kohrathy R, Parks RJ. A reduction in the human adenovirus virion size through use of a shortened fibre protein does not enhance muscle transduction following systemic or localised delivery in mice. Virology 2014; 468–470C: 444–453.
25 Campbell RE, Tour O, Palmer AE, Steinbach PA, Baird GS, Zacharias DA et al. A monomeric red fluorescent protein. Proc Natl Acad Sci U S A 2002; 99: 7787–7782.
26 Shaner NC, Campbell RE, Steinbach PA, Giepmans BN, Palmer AE, Tsien RY. Improved monomeric red, orange and yellow fluorescent proteins derived from Discosoma sp. red fluorescent protein. Nat Biotechnol 2004; 22: 1567–1572.
27 Ross PJ, Parks RJ. Construction and characterization of adenovirus vectors. CSF Protoc 2009; 2009: pdb prot5011.
28 Stojdl DF, Lichy BD, tenOever BR, Paterson JM, Power AT, Knowles S et al. HSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 2003; 4: 263–275.
29 Nanopoulos ER, Chen L, Anton M, Sankar U, Rudnicki MA, Graham FL. A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc Natl Acad Sci U S A 1996; 93: 13565–13570.
30 Corcoran JA, Clancy EK, Duncan R. Homomultimerization of the reovirus p14 fusion-associated small transmembrane protein promotes cancer cell fusion and apoptosis in vitro but does not provide therapeutically efficient in a xenograft mouse model of cancer. PLoS One 2016; 11: e0151516.
31 Ross PJ, Parks RJ. Extensive syncytium formation mediated by adenoviral vectors encoding measles virus fusogenic membrane proteins and cytokines. Cancer Gene Therapy 2007, 14(3): 263–275.
32 Stojdl DF, Lichty BD, tenOever BR, Paterson JM, Power AT, Knowles S et al. HSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 2003; 4: 263–275.
33 Parks RJ, Chen L, Anton M, Sankar U, Rudnicki MA, Graham FL. A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc Natl Acad Sci U S A 1996; 93: 13565–13570.
34 Corcoran JA, Clancy EK, Duncan R. Homomultimerization of the reovirus p14 fusion-associated small transmembrane protein during transit through the ER–Golgi complex secretory pathway. J Gen Virol 2011; 92: 162–166.
35 Bramson JL, Hitt M, Gauldie J, Graham FL. Pre-existing immunity to adenovirus does not prevent tumor regression following intratumoral administration of a vector expressing IL-12 but inhibits virus dissemination. Gene Ther 1997; 4: 1069–1076.
36. Worgall S, Wolff G, Falck-Pedersen E, Crystal RG. Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration. Hum Gene Ther 1997; 8: 37–44.

37. Addison CL, Hitt M, Kunsken D, Graham FL. Comparison of the human versus murine cytomegalovirus immediate early gene promoters for transgene expression by adenoviral vectors. J Gen Virol. 1997; 78(Pt 7): 1653–1661.

38. Higuchi H, Bronk SF, Bateman A, Harrington K, Vile RG, Gores GJ. Viral fusogenic membrane glycoprotein expression causes syncytia formation with bioenergetic cell death: implications for gene therapy. Cancer Res 2000; 60: 6396–6402.

39. Lewis JD, Shearer MH, Kennedy RC, Bright RK. Surrogate tumor antigen vaccination induces tumor-specific immunity and the rejection of spontaneous metastases. Cancer Res 2005; 65: 2938–2946.

40. Wietzmann MD. Functions of the adenovirus E4 proteins and their impact on viral vectors. Front Biosci 2005; 10: 1106–1117.

41. Lavoie JN, Nguyen M, Marcellus RC, Branton PE, Shore GC. E4orf4, a novel adenovirus death factor that induces p53-independent apoptosis by a pathway that is not inhibited by zVAD-fmk. J Cell Biol 1998; 140: 637–645.

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/